Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 341Ovarian Neoplasms 177Lung Neoplasms 171Breast Neoplasms 118Fallopian Tube Neoplasms 87Neoplasms 79Carcinoma, Ovarian Epithelial 69Squamous Cell Carcinoma of Head and Neck 51Small Cell Lung Carcinoma 49Triple Negative Breast Neoplasms 41Adenocarcinoma of Lung 41Head and Neck Neoplasms 40Neoplasm Metastasis 37Neuroblastoma 34Central Nervous System Neoplasms 33Endometrial Neoplasms 28Esophageal Neoplasms 27Carcinoma 27Brain Neoplasms 27Lymphoma 26Recurrence 25Lymphoma, Large B-Cell, Diffuse 25Urinary Bladder Neoplasms 24Parkinson Disease 4, Autosomal Dominant Lewy Body 24Adenocarcinoma, Bronchiolo-Alveolar 23Testicular Neoplasms 22Astrocytoma 22Melanoma 19Uterine Cervical Neoplasms 18Prostatic Neoplasms 18

Interventions

adavosertib 1Paclitaxel 1Gemcitabine 1Carboplatin 11-dodecylpyridoxal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation × Carboplatin × Clear all
NCT02272790 2023-10-03

Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

AstraZeneca

Phase 2 Completed
95 enrolled 61 charts
Gynecologic

Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡